Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Comparative Clinical Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer

NCT07108309 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT07108309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07108309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Comparative Clinical Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
Lead sponsor
Biocad
Phase
Phase 2
Overall status
Recruiting
Start date
July 15, 2024
Completion date
May 31, 2027
Enrollment
124 (estimated)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer